U/S-guided Continuous Quadratus Lumborum Block III in Percutaneous Nephrolithotomy

Ultrasound-guided Continuous Quadratus Lumborum Block III for Postoperative Analgesia in Percutaneous Nephrolithotomy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04800302

Enrollment

Registered

2021-03-16

Start date

2021-06-10

Completion date

2022-06-28

Last updated

2022-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Renal Stone, Surgery

Keywords

Quadratus Lumborum Block III, Ultrasound-guided, Percutaneous nephrolithotomy, Analgesia

Brief summary

Percutaneous nephrolithotomy (PCNL) is considered to be the first choice and a more conservative procedure than open stone surgery. Not only postoperative pain related to dilatation of the renal capsule and parenchymal tract, but also patient's discomfort & nephrostomy tube-related stress are reported to delay recovery time and increase the complication rates. This study is designed to provide postoperative analgesia by using ultrasound-guided continuous Quadratus Lumborum Block (QLB) III in patients undergoing PCNL and to assess pain scores & side effects with less opioids consumption.

Interventions

PROCEDUREContinous Quadratum Lumborum Block III

Continuous infusion of Bupivacaine 0.125 % at a rate of 0.1 ml/kg/hr (not exceeding 12 ml/hour), infused through a catheter inserted in the plane between quadratus lumborum & psoas major muscles with ultrasound guidance.

PROCEDURESingle dose Quadratum Lumborum Block III

Single injection of a mixture solution of 20 ml Bupivacaine 0.5% + 10 ml Lidocaine 2%, injected through a needle inserted at the posterior aspect of the quadratus lumborum muscle between it and erector spinae muscle with ultrasound guidance.

PROCEDUREIntra-venous Morphine

Intra-venous Morphine \[0.1 mg/kg\] as rescue analgesic shots when the Visual Analogue Score (VAS) for pain exceeds 4.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ASA I-II. * Scheduled for percutaneous nephrolithotomy (PCNL).

Exclusion criteria

* Patient refusal. * Coagulation disorders. * Skin lesions or infection at site of needle insertion. * Known allergy to local anesthetics or opioids. * Patients suffering from neurological or mental disease. * Procedure turned into open stone surgery. * Failure of identification by U/S. * Urinary tract malignancies. * Opioid consumption 48 hours before the operation.

Design outcomes

Primary

Measure	Time frame	Description
Morphine consumption.	24 hours	Total dose of Morphine (measured in mg) given intra-venously to the patient post-operatively.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026